HK192895A - Glycoproteinic conjugates having trivalent immunogenic activity - Google Patents

Glycoproteinic conjugates having trivalent immunogenic activity

Info

Publication number
HK192895A
HK192895A HK192895A HK192895A HK192895A HK 192895 A HK192895 A HK 192895A HK 192895 A HK192895 A HK 192895A HK 192895 A HK192895 A HK 192895A HK 192895 A HK192895 A HK 192895A
Authority
HK
Hong Kong
Prior art keywords
oligosaccharidic
immunogenic activity
trivalent
tive
bacterium
Prior art date
Application number
HK192895A
Other languages
English (en)
Inventor
Massimo Porro
Paolo Costantino
Original Assignee
Sclavo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sclavo Spa filed Critical Sclavo Spa
Publication of HK192895A publication Critical patent/HK192895A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
HK192895A 1985-07-05 1995-12-21 Glycoproteinic conjugates having trivalent immunogenic activity HK192895A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT21451/85A IT1187753B (it) 1985-07-05 1985-07-05 Coniugati glicoproteici ad attivita' immunogenica trivalente

Publications (1)

Publication Number Publication Date
HK192895A true HK192895A (en) 1995-12-29

Family

ID=11181972

Family Applications (1)

Application Number Title Priority Date Filing Date
HK192895A HK192895A (en) 1985-07-05 1995-12-21 Glycoproteinic conjugates having trivalent immunogenic activity

Country Status (8)

Country Link
US (1) US4711779A (fr)
EP (1) EP0208375B1 (fr)
JP (1) JPH07121870B2 (fr)
AT (1) ATE70187T1 (fr)
CA (1) CA1272952C (fr)
DE (1) DE3682838D1 (fr)
HK (1) HK192895A (fr)
IT (1) IT1187753B (fr)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755381A (en) * 1986-03-27 1988-07-05 Swiss Serum And Vaccine Institute Berne Klebsiella capsular polysaccharide vaccine
US5374426A (en) * 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (fr) * 1991-01-28 2004-11-16 Peter J. Kniskern Vaccin conjugue de polysaccharide contre les pneumocoques
CA2059693C (fr) * 1991-01-28 2003-08-19 Peter J. Kniskern Antigenes polysaccharides de streptococcus pneumoniae
WO1992016232A1 (fr) * 1991-03-12 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Conjugues de polysaccharide-proteine
US5370872A (en) * 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
NZ249704A (en) * 1992-02-11 1996-11-26 Jackson H M Found Military Med A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
EP0570682B1 (fr) * 1992-05-07 1997-07-23 American Cyanamid Company Glycoconjugates synthétiques d'antigènes de lipid A et leur utilisation comme vaccins
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
US5866132A (en) * 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
JPH11506110A (ja) * 1995-06-07 1999-06-02 アルバータ リサーチ カウンセル 免疫原性および免疫刺激性オリゴサッカライド組成物ならびにそれらの作製法および使用法
EP0831901B2 (fr) * 1995-06-07 2005-12-07 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccins comprenant un conjugue antigene de polysaccharide-proteine porteuse et une proteine porteuse libre
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
DK0939647T4 (da) * 1996-08-27 2006-10-23 Novartis Vaccines & Diagnostic Neisseria Meningitidis-serogruppe B-glycokonjugat og fremgangsmåde til anvendelse deraf
NZ502437A (en) * 1997-07-17 2001-11-30 Baxter Healthcare Sa Immunogenic conjugates comprising H. influenzae type b (Hib) polysaccharide-recombinant refolded meningococcal outer membrane protein (rPorB) conjugate
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
SE522715C2 (sv) 1998-06-02 2004-03-02 Ericsson Telefon Ab L M Portabel kommunikationsanordning med elektromekaniskt omvandlingsorgan samt ett batteripaket för densamma
EP1096952B1 (fr) 1998-07-15 2008-05-21 The Brigham And Women's Hospital, Inc. Vaccin de polysaccharide contre les infections a staphyloccoques
CA2714833A1 (fr) * 1998-07-20 2000-02-03 Edward Konadu (Deceased) Vaccins contre l'infection due a l'escherichia coli o157
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
RU2130779C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа Научно-производственная компания "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка и дифтерии
KR100704826B1 (ko) * 1998-08-19 2007-04-09 박스터 헬쓰케어 에스.에이. Ｎ-아크릴로일화된 폴리사카라이드를 사용하여 제조된백신으로서 사용하기에 적합한 면역원성β-프로피온아미도-결합 폴리사카라이드 단백질 컨쥬게이트
US6974581B1 (en) * 1998-12-15 2005-12-13 Aventis Pasteur Limited Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2004011027A1 (fr) * 2002-07-30 2004-02-05 Baxter International Inc. Vaccins multivalents chimeres a conjugue polysaccharidique
EP1524993B1 (fr) 2002-08-02 2013-03-06 GlaxoSmithKline Biologicals s.a. Composition vaccinale de neisseria comprenant une combinaison d'antigènes
AU2003274511B2 (en) 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
SI2395073T1 (sl) 2002-11-01 2017-12-29 Glaxosmithkline Biologicals S.A. Sušilni postopek
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2289546A3 (fr) 2003-01-30 2011-03-30 Novartis Vaccines and Diagnostics S.r.l. Vaccins injectables contre les multiples serogroupes du meningocoque
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
CA2539715C (fr) 2003-10-02 2015-02-24 Glaxosmithkline Biologicals S.A. Antigenes pertussis et leur utilisation dans la vaccination
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ATE506963T1 (de) 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen meningitis
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
US9402915B2 (en) 2004-04-30 2016-08-02 Glaxosmithkline Biologicals Sa Integration of meningococcal conjugate vaccination
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
TWI445545B (zh) 2005-04-08 2014-07-21 Wyeth Corp 多價肺炎球菌多醣-蛋白質共軛物組合物
BRPI0612669B8 (pt) 2005-06-27 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, composição, e composição liofilizada
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US20090010959A1 (en) 2005-12-22 2009-01-08 Ralph Leon Biemans Pneumococcal Polysaccharide Conjugate Vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
SI2004225T1 (sl) 2006-03-22 2012-08-31 Novartis Ag Reĺ˝imi za imunizacijo z meningokoknimi konjugati
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
EP1872791A1 (fr) 2006-06-30 2008-01-02 Institut Pasteur Utilisation de polysaccharides bactériens pour empêcher la formation d'un film biologique
EA016417B1 (ru) 2006-09-07 2012-04-30 Глаксосмитклайн Байолоджикалс С.А. Способ получения вакцины
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
KR101500771B1 (ko) * 2007-03-23 2015-03-18 와이어쓰 엘엘씨 스트렙토코커스 뉴모니아 협막 다당류를 제조하기 위한 단축 정제 방법
CA2685506A1 (fr) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccin
BRPI0813307C1 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, processo para fabricar a vacina
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009104097A2 (fr) 2008-02-21 2009-08-27 Novartis Ag Polypeptides fhbp à méningocoques
HUE029265T2 (en) 2008-10-27 2017-02-28 Glaxosmithkline Biologicals Sa Method of purifying carbohydrates from the group streptococci
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
BRPI0923006A2 (pt) 2008-12-17 2016-03-08 Novartis Ag vacinas meningococicas incluindo receptor de hemoglobina
EP2411045A1 (fr) 2009-03-24 2012-02-01 Novartis AG Combinaisons de protéine liant le facteur h de méningocoque et de conjugués de saccharide de pneumocoque
PL2411048T3 (pl) 2009-03-24 2020-11-16 Glaxosmithkline Biologicals Sa Adjuwantowe meningokokowe białko wiążące czynnik h
SG175092A1 (en) 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
US20120135037A1 (en) 2009-06-01 2012-05-31 Mizel Steven B Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
WO2011030218A1 (fr) 2009-09-10 2011-03-17 Novartis Ag Vaccins combinés contre les maladies des voies respiratoires
WO2011039631A2 (fr) 2009-09-30 2011-04-07 Novartis Ag Expression de polypeptides fhbp méningococciques
ES2812523T3 (es) 2009-09-30 2021-03-17 Glaxosmithkline Biologicals Sa Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
EP2519265B1 (fr) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Immunogènes de polysaccharide conjugués à des protéines porteuses de e. coli
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
CN102869377A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012072769A1 (fr) 2010-12-01 2012-06-07 Novartis Ag Epitopes rrgb de pneumocoque et combinaisons de variantes
CA2860331A1 (fr) 2010-12-24 2012-06-28 Novartis Ag Composes
BR112013022397A2 (pt) 2011-03-02 2017-09-26 Derek O’Hagan vacinas combinadas com doses menores de antígeno e/ou adjuvante
GB201106225D0 (en) 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
MX354924B (es) 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
CN104159603A (zh) 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN104736180A (zh) 2012-05-22 2015-06-24 诺华股份有限公司 脑膜炎球菌血清组x偶联物
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
BR112015007126A2 (pt) 2012-10-02 2017-08-08 Glaxosmithkline Biologicals Sa composição, método para induzir uma resposta imune, e, uso de uma composição
CA2886938A1 (fr) 2012-10-12 2014-04-17 Glaxosmithkline Biologicals S.A. Antigenes de pertussis acellulaires non reticules pour leur utilisation dans des vaccins combines
EP2938363B1 (fr) 2012-12-27 2019-08-21 GlaxoSmithKline Biologicals S.A. Procédés et compositions se rapportant à crm197
ITMI20130142A1 (it) * 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
PE20151720A1 (es) 2013-03-08 2015-12-10 Crucell Holland Bv Vacuna acelular contra pertussis
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
LT3110442T (lt) 2014-02-28 2020-12-28 Glaxosmithkline Biologicals Sa Modifikuoti meningokokinio fhbp polipeptidai
ES2672045T3 (es) * 2014-07-25 2018-06-12 Biosynth S.R.L. Vacunas de productos glicoconjugados que comprenden unidades básicas de una construcción molecular que expresa múltiples epítopos incorporados para la formulación de una vacuna de amplio espectro contra infecciones debidas a bacterias enteropatógenas
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (fr) 2014-12-19 2016-06-22 Novartis AG Purification de polysaccharides capsulaires de streptocoques
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
EP3474890A1 (fr) 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. Composition de conjugué polysaccharide pneumococcique-protéine
EP3269385A1 (fr) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composition de conjugués de polysaccharide-protéine pneumococcique
WO2018042017A2 (fr) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccins contre neisseria gonorrhoeae
JP6944946B2 (ja) 2016-10-20 2021-10-06 Ｋｍバイオロジクス株式会社 低分子化ＰＲＰを用いたＨｉｂコンジュゲートワクチンの製造方法
EP3551668A1 (fr) 2016-12-06 2019-10-16 GlaxoSmithKline Biologicals S.A. Procédé de purification pour polysaccharide capsulaire
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11400162B2 (en) 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
BR112020004410A8 (pt) * 2017-09-07 2023-01-31 Merck Sharp & Dohme Processos para a formulação de polissacarídeos pneumocócicos para conjugação a uma proteína carreadora
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
US20210269603A1 (en) 2018-07-19 2021-09-02 Glaxosmithkline Biologicals Sa Processes for preparing dried polysaccharides
EP3607967A1 (fr) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Polypeptides modifiés du méningocoque fhbp
JP2022513458A (ja) 2018-12-12 2022-02-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
US20220016229A1 (en) * 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
EP3923982A1 (fr) 2019-02-11 2021-12-22 Pfizer Inc. Compositions de neisseria meningitidiset procédés associées
EP3757217A1 (fr) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Procédés de purification de protéines
EP3777884A1 (fr) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Composition immunogène
CA3155669A1 (fr) 2019-09-27 2021-04-01 Pfizer Inc. Compositions de neisseria meningitidis et methodes associees
EP3799884A1 (fr) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Compositions immunogènes
EP3900739A1 (fr) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Conjugués saccharides synthétiques de streptococcus pneumoniae à une protéine de membrane conservée
EP3919076A1 (fr) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccins synthétiques d'oligosaccharide contre le streptococcus pneumoniae avec des formulations d'adjuvant de microparticules
BR112022023261A2 (pt) 2020-06-12 2022-12-27 Glaxosmithkline Biologicals Sa Imunização bacteriana usando vacina de nanopartícula
MX2022016589A (es) 2020-06-25 2023-02-01 Glaxosmithkline Biologicals Sa O-antigeno de klebsiella pneumoniae.
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
CA3196222A1 (fr) 2020-10-20 2022-04-28 Xianchao ZHU Conjugue de proteoglycane et son application
CA3201450A1 (fr) 2020-11-13 2022-05-19 Glaxosmithkline Biologicals Sa Transporteurs de proteine bacterienne et procedes de conjugaison
WO2023111826A1 (fr) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Immunisation bactérienne utilisant des constructions de nanoparticules en épingle à cheveux qbêta
WO2023118033A1 (fr) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccin
WO2023200704A1 (fr) 2022-04-11 2023-10-19 Sanofi Pasteur Inc. Conjugaison protéine-saccharide avec du cyanoborohydrure de sodium
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
AU561067B2 (en) * 1982-03-22 1987-04-30 Biocarb Ab Anti-bacterial composition containing an oligosaccharide
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4663160A (en) * 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria

Also Published As

Publication number Publication date
ATE70187T1 (de) 1991-12-15
DE3682838D1 (de) 1992-01-23
JPH07121870B2 (ja) 1995-12-25
EP0208375B1 (fr) 1991-12-11
US4711779A (en) 1987-12-08
EP0208375A2 (fr) 1987-01-14
JPS6230726A (ja) 1987-02-09
CA1272952A (fr) 1990-08-21
IT1187753B (it) 1987-12-23
IT8521451A0 (it) 1985-07-05
EP0208375A3 (en) 1989-04-05
CA1272952C (fr) 1990-08-21

Similar Documents

Publication Publication Date Title
EP0208375A3 (en) Glycoproteinic conjugates having trivalent immunogenic activity
ZA834939B (en) Heamophilus influenzae b polysaccharide exotoid conjugate vaccine
ZA859676B (en) Covalently-modified bacterial poly-saccharides,stable covalent conjugates of such polysaccharides and immunogenic proteins,and methods of preparing such polysaccharides and conjugates
ES8601702A1 (es) Un conjugado de polisacaridonproteina
AU8483391A (en) Improved oligosaccharide conjugate vaccines
NO2011019I1 (no) Vaksine omfattende antigenet PRP-T koplet til et tetanus anatoksin
FR12C0059I1 (fr)
AU4221485A (en) Covalently-modified bacterial poly-saccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugates and of confirming covalency
HUT35521A (en) Process for preparing a pharmaceutical composition containing a purified, detixicated endotoxine and a pyridine soluble extract of a microorganism
JPS56161330A (en) B group streptococcus capsular polysaccharide
GB2226563B (en) Streptolysin o antigen derivative,its production and uses
ES2006763A6 (es) Un metodo para preparar un toxoide inmunogenico.
EP0320942A3 (fr) Polysaccharides et composés macromoléculaires contenant ces polysaccharides
AU5045493A (en) Process for preparing conjugates consisting of a specific binding partner and a carbohydrate-containing protein
CA2141410A1 (fr) Production de vaccin anti-tetanique

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)